UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 9, 2004
La Jolla Pharmaceutical Company
| Delaware | 0-24274 | 33-0361285 | ||
| (State or Other Jurisdiction | (Commission | (IRS Employer | ||
| of Incorporation) | File Number) | Identification No.) | ||
| 6455 Nancy Ridge Drive, San Diego, California | 92121 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 452-6600
N/A
| Item 5. Other Events and Required FD Disclosure | ||||||||
| Item 7. Financial Statements, Pro Forma Financial Information and Exhibits | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EXHIBIT 99.1 | ||||||||
| EXHIBIT 99.2 | ||||||||
Item 5. Other Events and Required FD Disclosure.
On March 9, 2004, the Company issued a press release announcing that Steven Engle, the Company’s Chief Executive Officer, would present at the SG Cowen 24th Annual Healthcare Conference on March 11, 2004. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
On March 10, 2004, the Company issued a press release announcing that Gail Sloan was promoted to Vice President of Finance, Controller and Secretary. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits. The following exhibits are filed with this report on Form 8-K:
| Exhibit | ||
| Number |
Description of Exhibit |
|
99.1
|
Press Release announcing that the Company would present at the SG Cowen 24th Annual Healthcare Conference | |
99.2
|
Press Release announcing that Gail Sloan was promoted to Vice President of Finance, Controller and Secretary |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LA JOLLA PHARMACEUTICAL COMPANY |
||||
| Date: March 10, 2004 | By: | /s/ Gail A. Sloan | ||
| Gail A. Sloan | ||||
| Vice President of Finance and Controller | ||||